Rise in prevalence of infectious diseases such a tuberculosis and hepatitis along with sexually transmitted infections (STIs) such as chlamydia and gonorrhea is propelling the Europe molecular diagnostics market growth. Molecular diagnostic methods assist in early detection and treatment of infectious illnesses, allowing healthcare personnel to offer the best care and monitoring.
Development of molecular medicine innovations focused on personalized medicine is another prominent factor boosting the Europe molecular diagnostics market size. Personalized medicines are tailored therapeutic approaches based on individual patient characteristics, preferences, and comfort.
These are assisted by molecular diagnostics, as they allow for adequate time for treatment, monitoring, and recovery. Prominent market players are fostering strategic partnerships and acquiring smaller players to maintain their stronghold in the competitive region.
Molecular diagnostics is a term encompassing a set of approaches or techniques specially designed to analyze biological markers, such as body temperature and gene sequencing, at a molecular level to detect and identify mutations, pathogens, or markers for rare disorders.
Molecular testing technology utilizes microarray analysis and nucleic acid amplification to treat cancer, infectious diseases, and genetic disorders.
Advantages of molecular diagnostics include high specificity and precision, fast turnaround time, enhanced automation, and sensitive detection of low levels of pathogens or mutations.
Recent Europe molecular diagnostics market trends suggest a shift in focus toward personalized medicine and therapeutic treatment options.
Integration of point-of-care digital testing platforms and next-generation sequencing is gaining traction in the healthcare system in Europe, owing to the rise in the burden of infectious diseases in the region.
| Attribute | Detail |
|---|---|
| Market Drivers |
|
Incidence of infectious diseases such as HIV, tuberculosis, hepatitis, and sexually transmitted diseases (STDs) has been rising across the globe. This is creating lucrative molecular diagnostic market opportunities in Europe.
Precision diagnostics facilitate rapid and accurate detection of pathogens, which enables early diagnosis of illnesses. This allows medical professionals to plan the treatment in a personalized manner and spend adequate time on disease management.
Growth in migration to Europe, evolving antimicrobial resistance, and globalization are augmenting the need for timely detection, identification, treatment, and management of illnesses, thus advancing Europe molecular diagnostics market statistics.
According to the European Centre for Disease Prevention and Control, the region witnessed 23 million new infection cases of sexually transmitted diseases (STDs) in 2021. Chlamydia and Gonorrhea are infections prevalent in the region.
Molecular diagnostics advancements in Europe focus primarily on personalized medicines that refer to tailored treatment approaches influenced by individual traits and preferences of each patient.
Personalized medicine advancements in molecular diagnostics include growing applications in prenatal screening and liquid biopsy adoption in order to predict a patient’s response and monitor treatment efficacy.
Implementation challenges of molecular diagnostics in European healthcare systems include high costs associated with development of novel technologies and investments in specialized education of skilled professionals.
Regulations and policy framework involve European Union-wide standardization of molecular diagnostic practices across healthcare contexts, which is challenging based on the current transition state of healthcare infrastructure.
As per the European Commission, more than EUR 3.0 Bn has been spent on personalized medicine research and implementation in the EU in recent years.
| Attribute | Detail |
|---|---|
| Leading Country | Germany |
Germany accounted for the largest Europe molecular diagnostics market share in 2023. Increase in investments in biotechnology research and growth in government support for accessible healthcare are factors fueling the market dynamics of the country.
According to Bio Deutschland, R&D expenditure in the biotechnology and diagnostic sector witnessed a growth of 54.0% in 2021 compared to previous years, with investments amounting to nearly EUR 3.8 Bn.
As per the latest Europe molecular diagnostics market forecast, the industry in Spain is projected to grow at a steady pace during the period between 2024 and 2034. Rise in geriatric population, increase in migration toward urban centers, and growth in private investment in biotechnology are fostering market development in the country.
According to data made publicly available by the Government of Spain, 9.68 million people aged over 65 years reside in the country. In 2021, the government spent about 7.3% of total GDP on healthcare technology and access.
Companies operating in the Europe molecular diagnostics industry are investing significantly in development of infectious disease surveillance using molecular diagnostics and molecular pathology. These investments aim to meet the increase in demand driven by surge in migration and growing geriatric population.
Close collaborations with other firms and outsourcing are strategies that enable companies in the Europe molecular diagnostics market to expand their product portfolio. Merger & acquisition is also a key tactic implemented by the leading players to maintain their stronghold in the constantly evolving regional landscape.
Agilent Technologies, Inc., BD, Bio-Rad Laboratories, Inc., Danaher, Eppendorf SE, F. Hoffmann-La Roche Ltd., PerkinElmer, Inc., Tecan Trading AG, Thermo Fisher Scientific, Inc., and QIAGEN are dominant firms operating in this sector.
The Europe molecular diagnostics market report highlights parameters such as company overview, financial overview, product portfolio, business strategies, and business segments of the companies mentioned above.
| Attribute | Detail |
|---|---|
| Market Value in 2023 (Base Year) | US$ 5.9 Bn |
| Market Forecast Value in 2034 | US$ 17.3 Bn |
| Growth Rate (CAGR) | 10.2% |
| Forecast Period | 2024-2034 |
| Historical Data Available for | 2020-2022 |
| Quantitative Units | US$ Bn for Value and Units for Volume |
| Market Analysis | The qualitative analysis includes drivers, restraints, opportunities, key trends, key market indicators, Porter’s Five Forces analysis, value chain analysis, and SWOT analysis. Furthermore, at the country level, the qualitative analysis includes key trends, price trends, and key supplier analysis. |
| Competition Landscape |
|
| Format | Electronic (PDF) + Excel |
| Market Segmentation |
|
| Countries Covered |
|
| Companies Profiled |
|
| Customization Scope | Available upon Request |
| Pricing | Available upon Request |
It was valued at US$ 5.9 Bn in 2023
It is projected to grow at a CAGR of 10.2% from 2024 to 2034
Rise in prevalence of infectious diseases and advancements in personalized medicine
Germany dominated the regional landscape in 2023
Agilent Technologies, Inc., BD, Bio-Rad Laboratories, Inc., Danaher, Eppendorf SE, F. Hoffmann-La Roche Ltd., PerkinElmer, Inc., Tecan Trading AG, Thermo Fisher Scientific, Inc., and QIAGEN
1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Europe Molecular Diagnostics Market
4. Market Overview
4.1. Introduction
4.1.1. Product Definition
4.1.2. Industry Evolution/Developments
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Europe Molecular Diagnostics Market Analysis and Forecast, 2020-2034
5. Key Insights
5.1. Pipeline Analysis
5.2. Key Product/Brand Analysis
5.3. Key Mergers & Acquisitions
5.4. COVID-19 Pandemic Impact on Industry
6. Europe Molecular Diagnostics Market Analysis and Forecast, by Product
6.1. Introduction & Definition
6.2. Key Findings/Developments
6.3. Market Value Forecast, by Product, 2020-2034
6.3.1. Real-time PCR Systems
6.3.1.1. LightCycler 480
6.3.1.2. PCRmax Eco 48
6.3.1.3. Applied Biosystems 7900HT
6.3.1.4. QuantStudio Real-Time PCR
6.3.1.5. ViiA 7 Real-Time PCR
6.3.1.6. C1000 Touch
6.3.1.7. ABI StepOnePlus Real-Time PCR
6.3.1.8. 5ABI 7500
6.3.1.9. AriaMx Real-time PCR System
6.3.1.10. CFX Connect
6.3.1.11. CFX384 Touch
6.3.1.12. MiniOpticon
6.3.1.13. Others
6.3.2. Liquid Handling Systems
6.3.2.1. epMotion
6.3.2.2. Biomek
6.3.2.3. Freedom EVO
6.3.2.4. Tecan D300e Digital Dispenser
6.3.2.5. Precision
6.3.2.6. JANUS
6.3.2.7. Others
6.3.3. DNA Extraction Systems
6.3.3.1. AutoMate Express
6.3.3.2. QIAcube
6.3.3.3. InnuPure
6.3.3.4. VERSA
6.3.3.5. Chemagic
6.3.3.6. Others
6.4. Market Attractiveness Analysis, by Product
7. Europe Molecular Diagnostics Market Analysis and Forecast, by End-user
7.1. Introduction & Definition
7.2. Key Findings/Developments
7.3. Market Value Forecast, by End-user, 2020-2034
7.3.1. Hospitals
7.3.2. Diagnostics Laboratories
7.3.3. Academic & Research Institutes
7.3.4. Pharmaceutical & Biotechnology Companies
7.4. Market Attractiveness Analysis, by End-user
8. Europe Molecular Diagnostics Market Analysis and Forecast, by Country
8.1. Key Findings
8.2. Market Value Forecast, by Country, 2020-2034
8.2.1. Italy
8.2.2. Europe
8.2.3. U.K.
8.2.4. France
8.2.5. Germany
8.3. Market Attractiveness Analysis, by Country
9. Italy Molecular Diagnostics Market Analysis and Forecast
9.1. Introduction
9.2. Key Findings
9.3. Market Value Forecast, by Product, 2020-2034
9.3.1. Real-time PCR Systems
9.3.1.1. LightCycler 480
9.3.1.2. PCRmax Eco 48
9.3.1.3. Applied Biosystems 7900HT
9.3.1.4. QuantStudio Real-Time PCR
9.3.1.5. ViiA 7 Real-Time PCR
9.3.1.6. C1000 Touch
9.3.1.7. ABI StepOnePlus Real-Time PCR
9.3.1.8. 5ABI 7500
9.3.1.9. AriaMx Real-time PCR System
9.3.1.10. CFX Connect
9.3.1.11. CFX384 Touch
9.3.1.12. MiniOpticon
9.3.1.13. Others
9.3.2. Liquid Handling Systems
9.3.2.1. epMotion
9.3.2.2. Biomek
9.3.2.3. Freedom EVO
9.3.2.4. Tecan D300e Digital Dispenser
9.3.2.5. Precision
9.3.2.6. JANUS
9.3.2.7. Others
9.3.3. DNA Extraction Systems
9.3.3.1. AutoMate Express
9.3.3.2. QIAcube
9.3.3.3. InnuPure
9.3.3.4. VERSA
9.3.3.5. Chemagic
9.3.3.6. Others
9.4. Market Value Forecast, by End-user, 2020-2034
9.4.1. Hospitals
9.4.2. Diagnostics Laboratories
9.4.3. Academic & Research Institutes
9.4.4. Pharmaceutical & Biotechnology Companies
9.5. Market Value Forecast, by Country, 2020-2034
9.5.1. U.S.
9.5.2. Canada
9.6. Market Attractiveness Analysis
9.6.1. By Product
9.6.2. By End-user
10. Spain Molecular Diagnostics Market Analysis and Forecast
10.1. Introduction
10.2. Key Findings
10.3. Market Value Forecast, by Product, 2020-2034
10.3.1. Real-time PCR Systems
10.3.1.1. LightCycler 480
10.3.1.2. PCRmax Eco 48
10.3.1.3. Applied Biosystems 7900HT
10.3.1.4. QuantStudio Real-Time PCR
10.3.1.5. ViiA 7 Real-Time PCR
10.3.1.6. C1000 Touch
10.3.1.7. ABI StepOnePlus Real-Time PCR
10.3.1.8. 5ABI 7500
10.3.1.9. AriaMx Real-time PCR System
10.3.1.10. CFX Connect
10.3.1.11. CFX384 Touch
10.3.1.12. MiniOpticon
10.3.1.13. Others
10.3.2. Liquid Handling Systems
10.3.2.1. epMotion
10.3.2.2. Biomek
10.3.2.3. Freedom EVO
10.3.2.4. Tecan D300e Digital Dispenser
10.3.2.5. Precision
10.3.2.6. JANUS
10.3.2.7. Others
10.3.3. DNA Extraction Systems
10.3.3.1. AutoMate Express
10.3.3.2. QIAcube
10.3.3.3. InnuPure
10.3.3.4. VERSA
10.3.3.5. Chemagic
10.3.3.6. Others
10.4. Market Value Forecast, by End-user, 2020-2034
10.4.1. Hospitals
10.4.2. Diagnostics Laboratories
10.4.3. Academic & Research Institutes
10.4.4. Pharmaceutical & Biotechnology Companies
10.5. Market Attractiveness Analysis
10.5.1. By Product
10.5.2. By End-user
11. U.K. Molecular Diagnostics Market Analysis and Forecast
11.1. Introduction
11.2. Key Findings
11.3. Market Value Forecast, by Product, 2020-2034
11.3.1. Real-time PCR Systems
11.3.1.1. LightCycler 480
11.3.1.2. PCRmax Eco 48
11.3.1.3. Applied Biosystems 7900HT
11.3.1.4. QuantStudio Real-Time PCR
11.3.1.5. ViiA 7 Real-Time PCR
11.3.1.6. C1000 Touch
11.3.1.7. ABI StepOnePlus Real-Time PCR
11.3.1.8. 5ABI 7500
11.3.1.9. AriaMx Real-time PCR System
11.3.1.10. CFX Connect
11.3.1.11. CFX384 Touch
11.3.1.12. MiniOpticon
11.3.1.13. Others
11.3.2. Liquid Handling Systems
11.3.2.1. epMotion
11.3.2.2. Biomek
11.3.2.3. Freedom EVO
11.3.2.4. Tecan D300e Digital Dispenser
11.3.2.5. Precision
11.3.2.6. JANUS
11.3.2.7. Others
11.3.3. DNA Extraction Systems
11.3.3.1. AutoMate Express
11.3.3.2. QIAcube
11.3.3.3. InnuPure
11.3.3.4. VERSA
11.3.3.5. Chemagic
11.3.3.6. Others
11.4. Market Value Forecast, by End-user, 2020-2034
11.4.1. Hospitals
11.4.2. Diagnostics Laboratories
11.4.3. Academic & Research Institutes
11.4.4. Pharmaceutical & Biotechnology Companies
11.5. Market Attractiveness Analysis
11.5.1. By Product
11.5.2. By End-user
12. France Molecular Diagnostics Market Analysis and Forecast
12.1. Introduction
12.2. Key Findings
12.3. Market Value Forecast, by Product, 2020-2034
12.3.1. Real-time PCR Systems
12.3.1.1. LightCycler 480
12.3.1.2. PCRmax Eco 48
12.3.1.3. Applied Biosystems 7900HT
12.3.1.4. QuantStudio Real-Time PCR
12.3.1.5. ViiA 7 Real-Time PCR
12.3.1.6. C1000 Touch
12.3.1.7. ABI StepOnePlus Real-Time PCR
12.3.1.8. 5ABI 7500
12.3.1.9. AriaMx Real-time PCR System
12.3.1.10. CFX Connect
12.3.1.11. CFX384 Touch
12.3.1.12. MiniOpticon
12.3.1.13. Others
12.3.2. Liquid Handling Systems
12.3.2.1. epMotion
12.3.2.2. Biomek
12.3.2.3. Freedom EVO
12.3.2.4. Tecan D300e Digital Dispenser
12.3.2.5. Precision
12.3.2.6. JANUS
12.3.2.7. Others
12.3.3. DNA Extraction Systems
12.3.3.1. AutoMate Express
12.3.3.2. QIAcube
12.3.3.3. InnuPure
12.3.3.4. VERSA
12.3.3.5. Chemagic
12.3.3.6. Others
12.4. Market Value Forecast, by End-user, 2020-2034
12.4.1. Hospitals
12.4.2. Diagnostics Laboratories
12.4.3. Academic & Research Institutes
12.4.4. Pharmaceutical & Biotechnology Companies
12.5. Market Attractiveness Analysis
12.5.1. By Product
12.5.2. By End-user
13. Germany Molecular Diagnostics Market Analysis and Forecast
13.1. Introduction
13.2. Key Findings
13.3. Market Value Forecast, by Product, 2020-2034
13.3.1. Real-time PCR Systems
13.3.1.1. LightCycler 480
13.3.1.2. PCRmax Eco 48
13.3.1.3. Applied Biosystems 7900HT
13.3.1.4. QuantStudio Real-Time PCR
13.3.1.5. ViiA 7 Real-Time PCR
13.3.1.6. C1000 Touch
13.3.1.7. ABI StepOnePlus Real-Time PCR
13.3.1.8. 5ABI 7500
13.3.1.9. AriaMx Real-time PCR System
13.3.1.10. CFX Connect
13.3.1.11. CFX384 Touch
13.3.1.12. MiniOpticon
13.3.1.13. Others
13.3.2. Liquid Handling Systems
13.3.2.1. epMotion
13.3.2.2. Biomek
13.3.2.3. Freedom EVO
13.3.2.4. Tecan D300e Digital Dispenser
13.3.2.5. Precision
13.3.2.6. JANUS
13.3.2.7. Others
13.3.3. DNA Extraction Systems
13.3.3.1. AutoMate Express
13.3.3.2. QIAcube
13.3.3.3. InnuPure
13.3.3.4. VERSA
13.3.3.5. Chemagic
13.3.3.6. Others
13.4. Market Value Forecast, by End-user, 2020-2034
13.4.1. Hospitals
13.4.2. Diagnostics Laboratories
13.4.3. Academic & Research Institutes
13.4.4. Pharmaceutical & Biotechnology Companies
13.5. Market Attractiveness Analysis
13.5.1. By Product
13.5.2. By End-user
14. Competition Landscape
14.1. Market Player - Competitive Matrix (by Tier and Size of Companies)
14.2. Market Share Analysis, by Company (2023)
14.3. Company Profiles
14.3.1. Agilent Technologies, Inc.
14.3.1.1. Company Overview
14.3.1.2. Product Portfolio
14.3.1.3. SWOT Analysis
14.3.1.4. Financial Overview
14.3.1.5. Strategic Overview
14.3.2. BD
14.3.2.1. Company Overview
14.3.2.2. Product Portfolio
14.3.2.3. SWOT Analysis
14.3.2.4. Financial Overview
14.3.2.5. Strategic Overview
14.3.3. Bio-Rad Laboratories, Inc.
14.3.3.1. Company Overview
14.3.3.2. Product Portfolio
14.3.3.3. SWOT Analysis
14.3.3.4. Financial Overview
14.3.3.5. Strategic Overview
14.3.4. Danaher
14.3.4.1. Company Overview
14.3.4.2. Product Portfolio
14.3.4.3. SWOT Analysis
14.3.4.4. Financial Overview
14.3.4.5. Strategic Overview
14.3.5. Eppendorf SE
14.3.5.1. Company Overview
14.3.5.2. Product Portfolio
14.3.5.3. SWOT Analysis
14.3.5.4. Financial Overview
14.3.5.5. Strategic Overview
14.3.6. F. Hoffmann-La Roche Ltd.
14.3.6.1. Company Overview
14.3.6.2. Product Portfolio
14.3.6.3. SWOT Analysis
14.3.6.4. Financial Overview
14.3.6.5. Strategic Overview
14.3.7. PerkinElmer, Inc.
14.3.7.1. Company Overview
14.3.7.2. Product Portfolio
14.3.7.3. SWOT Analysis
14.3.7.4. Financial Overview
14.3.7.5. Strategic Overview
14.3.8. Tecan Trading AG
14.3.8.1. Company Overview
14.3.8.2. Product Portfolio
14.3.8.3. SWOT Analysis
14.3.8.4. Financial Overview
14.3.8.5. Strategic Overview
14.3.9. Thermo Fisher Scientific, Inc.
14.3.9.1. Company Overview
14.3.9.2. Product Portfolio
14.3.9.3. SWOT Analysis
14.3.9.4. Financial Overview
14.3.9.5. Strategic Overview
14.3.10. QIAGEN
14.3.10.1. Company Overview
14.3.10.2. Product Portfolio
14.3.10.3. SWOT Analysis
14.3.10.4. Financial Overview
14.3.10.5. Strategic Overview
List of Tables
Table 01: Europe Molecular Diagnostics Market Value (US$ Mn) Forecast, by Product, 2020-2034
Table 02: Europe Molecular Diagnostics Market Volume (Units) Forecast, by Product, 2020-2034
Table 03: Europe Molecular Diagnostics Market Value (US$ Mn) Forecast, by End-user, 2020-2034
Table 04: Europe Molecular Diagnostics Market Value (US$ Mn) Forecast, by Country, 2020-2034
Table 05: Italy Molecular Diagnostics Market Value (US$ Mn) Forecast, by Product, 2020-2034
Table 06: Italy Molecular Diagnostics Market Volume (Units) Forecast, by Product, 2020-2034
Table 07: Italy Molecular Diagnostics Market Value (US$ Mn) Forecast, by End-user, 2020-2034
Table 08: Italy Molecular Diagnostics Market Value (US$ Mn) Forecast, by Country, 2020-2034
Table 09: Spain Molecular Diagnostics Market Value (US$ Mn) Forecast, by Product, 2020-2034
Table 10: Spain Molecular Diagnostics Market Volume (Units) Forecast, by Product, 2020-2034
Table 11: Spain Molecular Diagnostics Market Value (US$ Mn) Forecast, by End-user, 2020-2034
Table 12: Spain Molecular Diagnostics Market Value (US$ Mn) Forecast, by Country/Sub-region, 2020-2034
Table 13: U.K. Molecular Diagnostics Market Value (US$ Mn) Forecast, by Product, 2020-2034
Table 14: U.K. Molecular Diagnostics Market Volume (Units) Forecast, by Product, 2020-2034
Table 15: U.K. Molecular Diagnostics Market Value (US$ Mn) Forecast, by End-user, 2020-2034
Table 16: U.K. Molecular Diagnostics Market Value (US$ Mn) Forecast, by Country/Sub-region, 2020-2034
Table 17: France Molecular Diagnostics Market Value (US$ Mn) Forecast, by Product, 2020-2034
Table 18: France Molecular Diagnostics Market Volume (Units) Forecast, by Product, 2020-2034
Table 19: France Molecular Diagnostics Market Value (US$ Mn) Forecast, by End-user, 2020-2034
Table 20: France Molecular Diagnostics Market Value (US$ Mn) Forecast, by Country/Sub-region, 2020-2034
Table 21: Germany Molecular Diagnostics Market Value (US$ Mn) Forecast, by Product, 2020-2034
Table 22: Germany Molecular Diagnostics Market Volume (Units) Forecast, by Product, 2020-2034
Table 23: Germany Molecular Diagnostics Market Value (US$ Mn) Forecast, by End-user, 2020-2034
Table 24: Germany Molecular Diagnostics Market Value (US$ Mn) Forecast, by Country/Sub-region, 2020-2034
List of Figures
Figure 01: Europe Molecular Diagnostics Market Size (US$ Mn) and Distribution (%), by Country, 2023 and 2034
Figure 02: Europe Molecular Diagnostics Market Revenue (US$ Mn), by Product, 2023
Figure 03: Europe Molecular Diagnostics Market Value Share, by Product, 2023
Figure 04: Europe Molecular Diagnostics Market Revenue (US$ Mn), by End-user, 2023
Figure 05: Europe Molecular Diagnostics Market Value Share, by End-user, 2023
Figure 06: Europe Molecular Diagnostics Market Value Share, by Country, 2023
Figure 07: Europe Molecular Diagnostics Market Value (US$ Mn) Forecast, 2023-2034
Figure 08: Europe Molecular Diagnostics Market Value Share Analysis, by Product, 2023 and 2034
Figure 09: Europe Molecular Diagnostics Market Attractiveness Analysis, by Product, 2023-2034
Figure 10: Europe Molecular Diagnostics Market Value Share Analysis, by End-user, 2023 and 2034
Figure 11: Europe Molecular Diagnostics Market Attractiveness Analysis, by End-user, 2023-2034
Figure 12: Europe Molecular Diagnostics Market Value Share Analysis, by Country, 2023 and 2034
Figure 13: Europe Molecular Diagnostics Market Attractiveness Analysis, by Country, 2023-2034
Figure 14: Italy Molecular Diagnostics Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), 2020-2034
Figure 15: Italy Molecular Diagnostics Market Value Share Analysis, by Product, 2023 and 2034
Figure 16: Italy Molecular Diagnostics Market Value Share Analysis, by End-user, 2023 and 2034
Figure 17: Italy Molecular Diagnostics Market Attractiveness Analysis, by Product, 2023-2034
Figure 18: Italy Molecular Diagnostics Market Attractiveness Analysis, by End-user, 2023-2034
Figure 19: Spain Molecular Diagnostics Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), 2020-2034
Figure 20: Spain Molecular Diagnostics Market Value Share Analysis, by Product, 2023 and 2034
Figure 21: Spain Molecular Diagnostics Market Value Share Analysis, by End-user, 2023 and 2034
Figure 22: Spain Molecular Diagnostics Market Attractiveness Analysis, by Product, 2023-2034
Figure 23: Spain Molecular Diagnostics Market Attractiveness Analysis, by End-user, 2023-2034
Figure 24: U.K. Molecular Diagnostics Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), 2020-2034
Figure 25: U.K. Molecular Diagnostics Market Value Share Analysis, by Product, 2023 and 2034
Figure 26: U.K. Molecular Diagnostics Market Value Share Analysis, by End-user, 2023 and 2034
Figure 27: U.K. Molecular Diagnostics Market Attractiveness Analysis, by Product, 2023-2034
Figure 28: U.K. Molecular Diagnostics Market Attractiveness Analysis, by End-user, 2023-2034
Figure 29: France Molecular Diagnostics Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), 2020-2034
Figure 30: France Molecular Diagnostics Market Value Share Analysis, by Product, 2023 and 2034
Figure 31: France Molecular Diagnostics Market Value Share Analysis, by End-user, 2023 and 2034
Figure 32: France Molecular Diagnostics Market Attractiveness Analysis, by Product, 2023-2034
Figure 33: France Molecular Diagnostics Market Attractiveness Analysis, by End-user, 2023-2034
Figure 34: Germany Molecular Diagnostics Market Size (US$ Mn) Forecast and Y-o-Y Growth (%), 2020-2034
Figure 35: Germany Molecular Diagnostics Market Value Share Analysis, by Product, 2023 and 2034
Figure 36: Germany Molecular Diagnostics Market Value Share Analysis, by End-user, 2023 and 2034
Figure 37: Germany Molecular Diagnostics Market Attractiveness Analysis, by Product, 2023-2034
Figure 38: Germany Molecular Diagnostics Market Attractiveness Analysis, by End-user, 2023-2034
Copyright © Transparency Market Research, Inc. All Rights reserved
Trust Online
Europe Molecular Diagnostics Market
